Literature DB >> 15950459

Divergent biological effects of estradiol and diethylstilbestrol in the prostate cancer cell line MOP.

Jean-Jacques Kalach1, Marie-Odile Joly-Pharaboz, Jacqueline Chantepie, Brigitte Nicolas, Françoise Descotes, Claire Mauduit, Mohamed Benahmed, Jean André.   

Abstract

The involvement of mutated androgen receptors (mut-AR) in the actions of estrogens in prostate cancer cells is controversial. This work was designed to determine the role of such receptors in the growth inhibition by estradiol (E2) and androgens of the MOP cell line, a derivative of the LNCaP cell line. Diethylstilbestrol (DES) was used as a "tool". E2 like DHT and R1881 inhibits MOP cell proliferation while DES does not. E2 and R1881 down regulate mut-AR mRNA, DES does not. E2 enhances mut-AR transcriptional activity less efficiently than R1881 while DES does not. E2 and R1881 up regulate PSA secretion in a dose-dependent manner, DES does it marginally at 10(-6)M. MOP cells express low amounts of ERalpha and ERbeta mRNA but neither DES nor E2 and R1881 do enhance ER transcriptional activity. DES and E2 bind to mut-AR with relative binding affinities which are respectively 1/175 and 1/10 that of DHT. The E2 and androgen-repressed proliferation is prevented by DES and by the anti-androgen bicalutamide. In LNCaP cells, DES prevents the androgen-enhanced proliferation. These results strongly suggest that: (a) the putative endogenous ERs are biologically inactive in MOP cells, (b) the E2-repressed proliferation results from hormone binding to mut-AR and, (c) DES is an anti-androgen in mut-AR expressing cell line.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950459     DOI: 10.1016/j.jsbmb.2005.02.012

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  7 in total

1.  Low-dose diethylstilbestrol for the treatment of advanced prostate cancer.

Authors:  Julia Clemons; L Michael Glodé; Dexiang Gao; Thomas W Flaig
Journal:  Urol Oncol       Date:  2011-07-27       Impact factor: 3.498

2.  Application of the McMurry coupling reaction in the synthesis of tri- and tetra-arylethylene analogues as potential cancer chemotherapeutic agents.

Authors:  Rajendra P Tanpure; Amanda R Harkrider; Tracy E Strecker; Ernest Hamel; Mary Lynn Trawick; Kevin G Pinney
Journal:  Bioorg Med Chem       Date:  2009-08-12       Impact factor: 3.641

3.  Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer.

Authors:  Ruth E Langley; Ian F Godsland; Howard Kynaston; Noel W Clarke; Stuart D Rosen; Rachel C Morgan; Philip Pollock; Roger Kockelbergh; El-Nasir Lalani; David Dearnaley; Mahesh Parmar; Paul D Abel
Journal:  BJU Int       Date:  2008-04-16       Impact factor: 5.588

4.  Inhibition of XO or NOX attenuates diethylstilbestrol-induced endothelial nitric oxide deficiency without affecting its effects on LNCaP cell invasion and apoptosis.

Authors:  Ji-Youn Youn; Andrew Nguyen; Hua Cai
Journal:  Clin Sci (Lond)       Date:  2012-10       Impact factor: 6.124

5.  Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis.

Authors:  David Vindrieux; Marie Réveiller; Jacqueline Chantepie; Sadok Yakoub; Catherine Deschildre; Alain Ruffion; Marian Devonec; Mohamed Benahmed; Renée Grataroli
Journal:  Cancer Cell Int       Date:  2011-12-02       Impact factor: 5.722

6.  A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer.

Authors:  J Shamash; A Davies; W Ansell; S Mcfaul; P Wilson; T Oliver; T Powles
Journal:  Br J Cancer       Date:  2008-01-08       Impact factor: 7.640

7.  Estrogen receptor alpha (ERα)-mediated coregulator binding and gene expression discriminates the toxic ERα agonist diethylstilbestrol (DES) from the endogenous ERα agonist 17β-estradiol (E2).

Authors:  Aziza Hussein Bakheit Adam; Laura H J de Haan; Ignacio Miro Estruch; Guido J E J Hooiveld; Jochem Louisse; Ivonne M C M Rietjens
Journal:  Cell Biol Toxicol       Date:  2020-02-22       Impact factor: 6.691

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.